TG Therapeutics, Inc. - TGTX STOCK NEWS

On April 27, 2023, TG Therapeutics (NASDAQ: TGTX) announced that the U.S. Centers for Medicare & Medicaid Services issued a permanent J-Code for BRIUMVI (ublituximab-xiiy), effective July 1, 2023. The permanent J-Code (J2329) simplifies the claims and reimbursement process for BRIUMVI, enhancing patient access to treatment for relapsing forms of multiple sclerosis (RMS). Michael S. Weiss, CEO, highlighted this milestone as significant for BRIUMVI's early launch phase. While J-Codes are crucial for reimbursement, BRIUMVI's safety profile includes warnings about potential infusion reactions and infections, with serious incidents reported in clinical trials. The company anticipates further updates during its first quarter earnings call.

TG Therapeutics (NASDAQ: TGTX) announced presentations of data from its ULTIMATE I & II Phase 3 trials evaluating BRIUMVI (ublituximab-xiiy) for relapsing forms of multiple sclerosis (RMS) at the American Academy of Neurology annual meeting. CEO Michael S. Weiss expressed satisfaction with the presentation of additional analyses and in-vitro characterizations of BRIUMVI. Key presentations by leading authors included efficacy data in treatment-naive participants and results in those with highly active disease. The trials, which enrolled 1,094 patients across 10 countries, showcased BRIUMVI's design to deplete B-cells efficiently. The company aims to share further exploratory analyses throughout the year, underlining BRIUMVI's potential in treating RMS.

TG Therapeutics (NASDAQ: TGTX) announced that the European Medicines Agency's CHMP recommended approval of BRIUMVI™ (ublituximab-xiiy) for adults with relapsing forms of multiple sclerosis (RMS) with active disease. This follows the FDA's approval in the U.S. in December 2022, making BRIUMVI the first anti-CD20 monoclonal antibody approved for this indication. The recommendation is based on successful outcomes from the ULTIMATE I & II Phase 3 trials, which showed BRIUMVI significantly reduced the annualized relapse rate compared to teriflunomide. A decision by the European Commission is anticipated in about two months.

TG Therapeutics (TGTX) plans to present data from the ULTIMATE I & II Phase 3 trials of BRIUMVI (ublituximab-xiiy) for treating relapsing forms of multiple sclerosis (RMS) at the American Academy of Neurology meeting from April 22-27, 2023. Key presentations include:

• Enhanced ADCC of Ublituximab on April 25.
• Efficacy in Treatment-Naive Participants on April 24.
• Subpopulation Analyses for Highly Active Disease on April 24.

The trials enrolled 1,094 patients across 10 countries and evaluated the drug's effectiveness against teriflunomide.

TG Therapeutics, Inc. (TGTX) announced its financial results for Q4 and full year 2022, highlighting a pivotal year with the FDA approval and launch of BRIUMVI for multiple sclerosis. Product revenue for 2022 was approximately $2.6 million, primarily from UKONIQ, which was withdrawn in May 2022. Research and development expenses decreased to $125.4 million from $222.6 million in 2021, while selling, general, and administrative expenses also fell to $70.0 million. The net loss narrowed to $198.3 million from $348.1 million in 2021. Cash reserves stood at $174.1 million, projected to fund operations into mid-2024.

TG Therapeutics will host a conference call on February 28, 2023, at 8:30 AM ET to discuss its 2022 fourth-quarter and year-end results and provide a business outlook for 2023. The call will be led by Michael S. Weiss, the company’s Chairman and CEO. Participants can join the call by dialing 1-877-407-8029 within the U.S. or 1-201-689-8029 from outside the U.S.

A live webcast will be available on TG Therapeutics' website, and a recording will be accessible for 30 days post-call. The company focuses on developing treatments for B-cell diseases and has received FDA approval for BRIUMVI™ for specific multiple sclerosis conditions.

TG Therapeutics (TGTX) announced the presentation of data from the ULTIMATE I & II Phase 3 trials of BRIUMVI™ (ublituximab-xiiy) for treating adult patients with relapsing multiple sclerosis at the 2023 ACTRIMS conference. The trials enrolled 1,094 patients across 10 countries, showcasing BRIUMVI's potential in managing RMS. CEO Michael S. Weiss expressed optimism about the data's implications for BRIUMVI's market position, which is now commercially available. The presentations included analyses on hematologic parameters and disease activity, reinforcing BRIUMVI's therapeutic attributes as TG Therapeutics aims to expand its market presence.

TG Therapeutics, Inc. (NASDAQ: TGTX) has announced the upcoming presentations of data from the ULTIMATE I & II Phase 3 trials of BRIUMVI™ (ublituximab) for relapsing forms of multiple sclerosis (RMS) at the ACTRIMS annual forum on February 23-25, 2023, in San Diego. These trials involved 1,094 patients treated over 96 weeks, comparing BRIUMVI to teriflunomide. Key presentations include findings on hematologic parameters and disease activity maintenance. BRIUMVI is a novel monoclonal antibody aimed at effectively managing RMS and has received FDA approval. Data from these presentations will be pivotal for investors and patients alike.

TG Therapeutics has launched BRIUMVI™ (ublituximab-xiiy), the first anti-CD20 monoclonal antibody approved for treating relapsing forms of multiple sclerosis (RMS) in adults. BRIUMVI requires only a one-hour infusion after the initial dose and is supported by a comprehensive patient assistance program. The drug's approval is based on positive results from the ULTIMATE I & II Phase 3 trials, demonstrating its effectiveness in significantly reducing the annualized relapse rate compared to teriflunomide. TG Therapeutics emphasizes its commitment to patient accessibility and support during treatment.